



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Jessica Teeling, Sigrid Ruuls, Martin Glennie, Jan G. J. van de Winkel, Paul Parren, J rgen Petersen, Ole Baadsgaard, and Haichun Huang

Application No.: 10/687,799


Group: 1644

Filed: October 17, 2003

Examiner: Ronald B. Schwadron

Confirmation No: 1801

For: Human Monoclonal Antibodies Against CD20

CERTIFICATE OF MAILING OR TRANSMISSION	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:	
10/1/2007 Date	 Signature
Katherine J. Kantorski	
Typed or printed name of person signing certificate	

TRANSMITTAL OF SUBSTITUTE SEQUENCE LISTING IN RESPONSE TO NOTICE TO COMPLY WITH 37 C.F.R   1.821-1.825 AND PRELIMINARY AMENDMENT

Mail Stop Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This amendment is submitted in response to the Notice to Comply with Sequence Requirements mailed from the Patent Office on May 1, 2007. A copy of the Notice to Comply is enclosed.

Reconsideration and further examination are requested.

Applicant's Attorney requests an extension of time to respond to the Notice. A Petition for Extension of Time and the appropriate fees are being filed concurrently.

Transmitted herewith is a copy of the "Substitute Sequence Listing" (sheet 1/27 through 27/27, comprising SEQ ID NOS:1-95) in paper form for the above-referenced patent application as required by 37 C.F.R.   1.821(c), and a copy of the "Substitute Sequence Listing" in computer

readable form as required by 37 C.F.R. §1.821(e). Please insert the attached "Substitute Sequence Listing" into the application.

As required by 37 C.F.R. §1.821(f), Applicant's Attorney hereby states that the content of the "Sequence Listing" in paper form and the computer readable form of the "Sequence Listing" are the same and, as required by 37 C.F.R. §1.821(g), also states that the submission includes no new matter.

The following amendments are being submitted to comply with 37 CFR §§ 1.821 - 1.825. Please amend the application as follows: